Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript

SA Transcripts158.91K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Spyre Therapeutics, Inc. (SYRE) Leerink Global Healthcare Conference 2026 March 9, 2026 8:40 AM EDT Company Participants Cameron Turtle - CEO & DirectorSheldon Sloan - Chief Medical Officer Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Presentation Thomas SmithLeerink Partners LLC, Research Division Good morning, everyone. Thanks for joining us here at the Leerink Partners Global Healthcare Conference. My name is Tom Smith. I'm one of the senior biotech analysts here at Leerink. And it's my pleasure to introduce our next company, Spyre Therapeutics and their management team led by CEO, Cameron Turtle; and CMO, Sheldon Sloan. Gentlemen, thanks for joining us. Cameron TurtleCEO & Director Thanks for having us. Thomas SmithLeerink Partners LLC, Research Division And this is one of our top picks for 2026. We think this company is really best positioned to capitalize on the emergence of combination therapies in inflammatory bowel disease. And we also see the potential for TL1A to be a potential game changer in rheumatology indications. Spyre is interrogating both of those theses intensively, and we're going to get a lot of data here over the next 9 months. We have 6 Phase II readouts this year. So a lot of data catalysts coming. And we think we're going to start to see that thesis prove out. Cameron, why don't you kick us off with -- I know I just gave a little bit of a background, but maybe like a little bit of an overview for those in the audience who are a little bit less familiar with the story? Cameron TurtleCEO & Director Yes, you did it well. But I think the short version here is that we're looking to create indication-leading products across the large autoimmune disease markets. And we started this by making what